Paula Perkins

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton et al. · Journal of Medicinal Chemistry · 2014 · 602 citations · Full text

Medicine, Oncology, Pharmacology +15

Discovery of 4-{4-[(3<i>R</i>)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1<i>H</i>-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity

Kevin M. Foote, Kevin Blades, Anna Cronin et al. · Journal of Medicinal Chemistry · 2013 · 215 citations · Full text

Medicine, Oncology, Pharmacology +13

Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation

Jon Winter, Malcolm Anderson, Kevin Blades et al. · Journal of Medicinal Chemistry · 2015 · 120 citations

Life Sciences, Biochemistry, Molecular Biology +17

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Jordan Gauthier, Nicolas Gazeau, Alexandre V. Hirayama et al. · Blood · 2022 · 54 citations · Full text

Life Sciences, Immunology, Oncology +13

Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor

M. Raymond V. Finlay, David Buttar, Susan E. Critchlow et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 33 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11